Foundation Medicine Establishes Immuno-Oncology Companion Diagnostics Collaboration with Merck
-- Pan-Cancer MSI Companion Diagnostic for KEYTRUDA® (pembrolizumab) Planned for Inclusion on FoundationOne CDx™--
“By collaborating, Merck and
“Rapidly evolving knowledge of cancer biology and immuno-oncology continues to improve understanding of how to deploy our medicines to identify those patients most likely to respond effectively,” said Dr.
FoundationOne CDx, an
FoundationOne CDx is available to order online at www.foundationmedicine.com/genomic-testing/order, or visit https://home.foundationmedicine.com/signup to sign up for an account.
About FoundationOne CDx
FoundationOne CDx is a next-generation sequencing based in vitro diagnostic device for detection of substitutions, insertion and deletion alterations (indels), and copy number alterations (CNAs) in 324 genes and select gene rearrangements, as well as genomic signatures including microsatellite instability (MSI) and tumor mutational burden (TMB) using DNA isolated from formalin-fixed paraffin embedded (FFPE) tumor tissue specimens. FoundationOne CDx is intended as a companion diagnostic to identify patients who may benefit from treatment with certain targeted therapies in accordance with their approved therapeutic product labeling. Additionally, FoundationOne CDx is intended to provide tumor mutation profiling to be used by qualified health care professionals in accordance with professional guidelines in oncology for patients with solid malignant neoplasms. For a full list of targeted therapies for which FoundationOne CDx is indicated as a companion diagnostic, please visit http://www.foundationmedicine.com/genomic-testing/foundation-one-cdx.
About
Cautionary Note Regarding Forward-Looking Statements for
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding a collaboration between Merck and
View source version on businesswire.com: https://www.businesswire.com/news/home/20180524005237/en/
Source:
Foundation Medicine, Inc.
Media:
Lee-Ann Murphy, 617-245-3077
pr@foundationmedicine.com
or
Investor:
Kimberly Brown, 617-418-2215
ir@foundationmedicine.com